^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Small Cell Lung Cancer
    Drug:Lytgobi (futibatinib) (FGFR inhibitor) +
    pifusertib (TAS-117) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 661: Synergistic antitumor activity of futibatinib, an FGFR1-4 inhibitor, and TAS-117, a selective AKT inhibitor, in FGFR-deregulated cancer models

    Published date:
    05/15/2020
    Excerpt:
    Effects of futibatinib plus TAS-117 were investigated in human endometrial FGFR2-N549K-mutated AN3CA cancer cells and small-cell lung cancer FGFR1-amplified DMS114 cells...Futibatinib and TAS-117 synergistically increased cell death and decreased cell growth in AN3CA (CI<0.40) and DMS114 (CI<0.40) cells, respectively...Our findings suggest that futibatinib plus TAS-117 has synergistic antitumor effects in FGFR-aberrant tumors.
    DOI:
    10.1158/1538-7445.AM2020-661